Connect with us

China

Two Chinese Spies Charged for Hacking Sensitive COVID-19 Research

Published

on

Screen Shot 2020 07 21 at 2.29.12 PM

Two Chinese nationals have been charged by the U.S. Department of Justice for a decade-long spying and intelligence-stealing operation. The indictment claims Li Xiaoyu and Dong Jiazhi stole data from large tech companies in different countries, including the U.S. for years, and recently attempted to steal information on coronavirus vaccine developments from U.S. companies.

Firms in Maryland, Massachusetts, and California working on vaccines were targeted by the Chinese spies, as reported by Tech Crunch.

XiaoyuWeb

The pair hacked a Department of Energy network in Washington state, leading to their discovery by U.S. officials. Using different holes in software and password-stealing viruses, they dove deep into company and government databases, collecting secrets and data worth millions of dollars, according to the indictment.

Important U.S. military information was accessed as well.

“Li and Dong stole information regarding military satellite programs; military wireless networks and communications systems; high powered microwave and laser systems; a counter-chemical weapons system; and…helicopter integration systems,” reads the indictment.

U.S. Assistant Attorney General for National Security John C. Demers said to Tech Crunch “that the indictments were ‘concrete examples’ of how China used hackers to ‘rob, replicate and replace’ non-Chinese companies in the global marketplace.”

The pair is reportedly in mainland China currently, so the indictments may lead to little action, according to reports.

The disturbing news comes as the topic of China heats up on the campaign trail. Vice President Mike Pence recently said “Biden Pretends To Be Tough On China.”

You may like

Continue Reading

China

FDA will work with China to import cancer drugs due to U.S. shortages

Published

on

FinalFDAshutterstock 1044596995

Earlier this week the United States Food and Drug Administration (FDA) announced it will be working to import chemotherapy drugs from, of all places, China. The drug, called Cisplatin, is to help “ramp up supply amidst rampant drug shortages in the U.S.” reports Foreign Desk News.

Foreign Desk News writes:

Cisplatin comes from drugmaker Qilu Pharmaceutical, which is marketed and produced in China but has not been approved by the FDA. According to a May 24 letter, Qilu will work with the Canadian-based drug company Apotex to import and distribute the medication, which will come in 50-milligram vials with Chinese labels.

“The FDA is responding to yet another generic drug shortage,” said Edmund F. Haislmaier, an expert in healthcare policy and markets at The Heritage Foundation. “The underlying cause of those shortages is that generic drugs have become low-margin commodity products,” he added.

Last week on Twitter, FDA commissioner Dr. Robert Califf said the partnership with Qilu Pharmaceutical is temporary but will provide patients with a potentially life-extending drug.

“The public should rest assured that we will continue all efforts within our authority to help the industry that manufactures and distributes these drugs meet all patient needs for the oncology drugs impacted by shortages,” Califf said.

Foreign Desk News adds:

The latest move by the FDA is sure to spark concern and debate in Congress, as lawmakers in the House and Senate have called on the Biden administration to de-couple the U.S. economy from the Chinese markets, given Beijing’s aggressive push to expand in the South-China Sea and eventually take over the island state of Taiwan. China has also spread illegal and dangerous synthetic opioids and fentanyl drugs across the U.S. southern border, resulting in the devastating deaths of many Americans.

 

You may like

Continue Reading
Advertisement
-->

Trending Now

Advertisement
-->

Trending